Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
- 12 February 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (7) , 1412-1421
Abstract
The effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m2 rituximab followed by 2 fractions of 131I-rituximab, preceded by a 100-mg/m2 predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of 131I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of 131I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent 131I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of 131I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.Keywords
This publication has 39 references indexed in Scilit:
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbBlood, 2008
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complementBlood, 2008
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911Journal of Clinical Oncology, 2006
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Non-Hodgkin Lymphoma: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomabSeminars in Oncology, 2003
- Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood, 2003
- Advantage of Dose Fractionation in Monoclonal Antibody-Targeted RadioimmunotherapyJNCI: Journal of the National Cancer Institute, 1990